Dr. Brian Helfand on the SPOTLIGHT Study: Recurrent Prostate Cancer Detection With 18F-rhPSMA-7.3

Brian Helfand, MD, PhD, NorthShore University HealthSystem, details the intended purpose of ¹⁸F-rhPSMA-7.3, how it compares to other PSMA PET radiopharmaceuticals or conventional imaging modalities, its ability to detect really distant disease, and how this is likely to impact treatment and patient management in the future.

In May 2023, ¹⁸F-rhPSMA-7.3 became the first FDA-approved radiohybrid PSMA-targeted PET imaging agent. ¹⁸F-rhPSMA-7.3 is an optimized diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer with suspected metastasis or suspected recurrence based on elevated serum PSA level or who are candidates for initial definite therapy.